Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell Centers

Novartis

Status: Completed

Conditions: Sickle Cell Disease

Study type: Observational

Funder types: Industry

Identifiers

NCT06662825

CSEG101AUS20

Details and patient eligibility

About

This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with patients who had initiated crizanlizumab between 2019 and 2022.

Enrollment: 376 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion criteria

• Any patient with a diagnosis of SCD based on high performance liquid chromatography (HPLC) or hemoglobin electrophoresis at treating institution.
• Treatment order for crizanlizumab; Index date was defined as the date for the first crizanlizumab treatment.
• At least 12 months of available electronic medical record (EMR) data pre-index date (baseline).
• Patients must have received at least one dose of crizanlizumab.
• For inclusion in pre/post analysis of effectiveness, patients must have received crizanlizumab for at least 12 months.

Exclusion criteria None identified.

Trial design

376 participants in 1 patient group

Crizanlizumab Cohort

Description:

Patients with sickle cell disease (SCD) who had received at least one dose of crizanlizumab between 2019 and 2022.